Initiator Pharma A/S Total Liabilities
Initiator Pharma A/S total liabilities. Based on the latest financial reports, Initiator Pharma A/S (INIT) has total liabilities worth Skr4.37 Million SEK (≈ $470.28K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Initiator Pharma A/S (INIT) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Initiator Pharma A/S (2016–2024)
Total liabilities of Initiator Pharma A/S from 2016 to 2024. This chart illustrates how Initiator Pharma A/S's total liabilities have evolved over time, based on quarterly financial data.
Initiator Pharma A/S Competitors by Total Liabilities
The table below lists competitors of Initiator Pharma A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
StarFlex Co. Ltd
KQ:115570
|
Korea | ₩29.18 Billion |
|
Image Resources NL
AU:IMA
|
Australia | AU$120.74 Million |
|
Wilton Resources Inc
V:WIL
|
Canada | CA$668.49K |
|
Giyani Metals Corp
V:EMM
|
Canada | CA$40.22 Million |
|
Greenland Mines Ltd
NASDAQ:GRML
|
USA | $7.11 Million |
|
TCS Group Holdings Bhd
KLSE:0221
|
Malaysia | RM209.67 Million |
|
Purefun Group AB
ST:PURE
|
Sweden | Skr36.40 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Initiator Pharma A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Initiator Pharma A/S assets under control.
Liquidity & Leverage Metrics
Initiator Pharma A/S Total Liabilities Ratios Explained
Initiator Pharma A/S total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Initiator Pharma A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Initiator Pharma A/S (2016–2024)
The table below shows the annual total liabilities of Initiator Pharma A/S from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr510.00K ≈ $54.88K |
-97.26% |
| 2023-12-31 | Skr18.62 Million ≈ $2.00 Million |
+30.04% |
| 2022-12-31 | Skr14.32 Million ≈ $1.54 Million |
-23.44% |
| 2021-12-31 | Skr18.71 Million ≈ $2.01 Million |
+1466.75% |
| 2020-12-31 | Skr1.19 Million ≈ $128.49K |
-21.96% |
| 2019-12-31 | Skr1.53 Million ≈ $164.65K |
+101.85% |
| 2018-12-31 | Skr758.00K ≈ $81.57K |
-77.26% |
| 2017-12-31 | Skr3.33 Million ≈ $358.79K |
+256.96% |
| 2016-12-31 | Skr934.00K ≈ $100.51K |
-- |
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more